Clinical trial
International Multicenter Phase I Trial of Hydroxyurea in Combination With Dose-Intense Temozolomide in Recurrent Glioblastoma
NCT03463733 is registered in ClinicalTrials.gov with M.E. van Linde as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- International Multicenter Phase I Trial of Hydroxyurea in Combination With Dose-Intense Temozolomide in Recurrent Glioblastoma
- Lead sponsor
- M.E. van Linde
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 2, 2018
- Completion date
- June 1, 2022
- Enrollment
- 54 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.